DR65 DataRelease
Release Date: June 2026
New Studies: 20
Updated Studies: 13
New Studies
| SDY621: Registry for the Atopic Dermatitis Research Network (ADRN-02) | ||||||||||
| Status: | New | |||||||||
| Description: | People with atopic dermatitis (AD), also known as eczema, experience hot, dry, scaly skin with severe itching. In addition, people with AD are prone to skin infections and inflammation. Little is known about the causes of AD or why people with AD are more prone to infections. The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3BWTEJ0L4 | |||||||||
| Subjects: | 3611 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY1845: Effect of Dupilumab (anti-IL4Ralpha) on the Host-Microbe Interface in Atopic Dermatitis (ADRN-09) | |||||||
| Status: | New | ||||||
| Description: | This is a multi-center, randomized, double-masked, placebo-controlled trial investigating the effect of 6 weeks of dupilumab treatment on quantitative and qualitative measures of cutaneous microbial community structure, skin barrier biology, and circulating T cell profiles, in adults with chronic moderate-to-severe atopic dermatitis (AD). After obtaining informed consent, eligible participants will return to clinic for their Treatment Initiation Visit (Day 0) and will be randomized 2:1 active to placebo. Participants will receive three doses of dupilumab or placebo based on their randomization assignment. The first dose (600 mg loading dose of dupilumab or placebo) will be administered on Day 0 and the second and third doses (300 mg dupilumab or placebo) on Day 14 and Day 28, respectively. Participants will return to clinic on Days 3, 7, and 21 during the double-masked portion of the study. Participants will begin the open-label extension (OLE) at Day 42 and will receive dupilumab (600 mg loading dose [two 300 mg injections] for those initially randomized to the placebo group and a 300 mg dose plus placebo injection for those initially randomized to the dupilumab group). Participants will return to clinic on Days 77 and 112 during the OLE portion of the study. During all visits (Day 0-Day 112), Adverse Events (AEs), concomitant medications, and medical history will be assessed and physical exams including assessment of AD severity will be performed. Blood, urine, skin swabs, skin tape strips, and skin biopsies, as applicable, will be collected, and barrier assessments will be performed per the Schedule of Events, per protocol. Samples will be collected prior to dupilumab or placebo administration on Days 0, 14, 28, and 42. After Day 112, a follow-up call (Day 182) will be made to assess for pregnancy, current medications, and adverse events (AEs). | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3PD2D0U9K | ||||||
| Subjects: | 103 | ||||||
| Study PI, contact: |
|
||||||
| Publications: | None | ||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3306: Protein networks are influenced by maternal BMI and differentiate preterm birth types | |||||||||||||
| Status: | New | ||||||||||||
| Description: | We conducted a study on a prospectively enrolled cohort of 100 pregnant individuals (30 spontaneous preterm birth, 30 medically-indicated preterm birth, 40 uncomplicated term deliveries) in which we profiled second-trimester plasma using a 7K SomaScan v4.1 aptamer-based proteomic assay to identify second-trimester maternal plasma proteomic signatures distinguishing spontaneous and medically-indicated preterm birth and to determine how body mass index modifies these profiles. Data revealed distinct proteomic profiles between spontaneous and medically indicated preterm birth, with obesity emerging as a key modifier of these molecular signatures. These findings offer new insight into obesity-related pathways involved in preterm birth. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3LI1BOAUL | ||||||||||||
| Subjects: | 100 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY3367: OMIP: A 28-color panel for classical and non-classical T lymphocytes in decidua and PBMC in rhesus macaques | |||||||||||||
| Status: | New | ||||||||||||
| Description: | This 28-color panel was developed to identify classical and non-classical T lymphocytes in decidual leukocytes and peripheral blood mononuclear cells (PBMC) of pregnant rhesus macaques. By profiling these T lymphocytes, we can investigate how maternal immunity balances tolerance to fetal antigens with protection against vertically transmitted pathogens. The selected markers define memory populations and characterize tissue residency, activation, proliferation, cytotoxicity, trafficking, and exhaustion status. This panel also delineates B lymphocytes and NK cells to confirm expected frequencies. The utility of this panel is aimed at evaluating cellular immune correlates of protection against congenital infections at the maternal-fetal interface and PBMC in rhesus macaques. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3VPLVHOH3 | ||||||||||||
| Subjects: | 0 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: | None | ||||||||||||
| Resources: |
|
||||||||||||
| Assays: | None | ||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY3402: ChAllenging to Food with Escalating ThrEsholds for ReducIng Food Allergy (CAFETERIA) | |||||||||||||||||||||||||||||||
| Status: | New | ||||||||||||||||||||||||||||||
| Description: | This is a prospective two-arm, parallel-group, randomized (1:1) controlled open trial of a diet allowing ingestion of tolerated, home-purchased, home-measurable quantities of peanut in children allergic to peanut in higher amounts. The primary objective of this study is to determine whether allowing ingestion of sub-threshold amounts of peanut in those with a high threshold (tolerate at least 143 mg peanut protein on supervised double-blind, placebo-controlled oral food challenge [DBPCFC]) will be associated with attaining even higher thresholds over time in children with high threshold peanut allergy compared to those avoiding peanut. The secondary clinical objectives include assessing the development of sustained unresponsiveness (SU, a surrogate term for tolerance without daily ingestion), effects on quality of life, and safety compared to those avoiding peanut. Additionally, this study will phenotype the allergic response to peanut based on threshold and response to exposure. Mechanistic study objectives will determine the immune and molecular basis of the high threshold endotype, identify predictors of response to exposure, and determine mechanisms and biomarkers of remission. | ||||||||||||||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||||||||||||||
| DOI: | 10.21430/M34BZ9R655 | ||||||||||||||||||||||||||||||
| Subjects: | 73 | ||||||||||||||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||||||||||||||
| Publications: | None | ||||||||||||||||||||||||||||||
| Resources: |
|
||||||||||||||||||||||||||||||
| Assays: | None | ||||||||||||||||||||||||||||||
| Clinical Assessments: |
|
||||||||||||||||||||||||||||||
| Release Notes: |
|
||||||||||||||||||||||||||||||
| SDY3470: Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus | ||||||||||
| Status: | New | |||||||||
| Description: | The authors conducted household transmission studies in Managua, Nicaragua, to assess the impact of anti-NA and anti-HA antibodies induced by natural infection on influenza A/H3N2 susceptibility and infectivity | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3Y5IBK5YS | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3472: Timing of de novo vaccination during pregnancy impacts maternal and newborn immunity | ||||||||||
| Status: | New | |||||||||
| Description: | This study examined how the timing of COVID-19 mRNA vaccination during pregnancy shapes maternal antibody responses and transplacental antibody transfer using comprehensive systems serology profilling in 263 pregnant individuals, including 96 maternal–neonatal dyads. Vaccine responses varied by gestational timing, with attenuated initial responses in third-trimester vaccinees but optimal antibody transfer when vaccination occurred in the late second to early third trimester, influenced further by fetal sex. Overall, the findings highlight gestational timing as a key determinant of effective maternal and neonatal immunity. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M396B0IQPV | |||||||||
| Subjects: | 328 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3504: Breast milk antibody Fc features linked to HIV transmission during breastfeeding | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Breastfeeding shapes early immunity, but without antiretroviral therapy (ART), carries a risk of HIV transmission. The role of breast milk antibodies in this process remains unclear. Using systems serology, we profiled milk antibodies from transmitting and non-transmitting mothers in the Zambia Exclusive Breastfeeding Study. Transmission was linked to higher gp41-specific IgG1 and increased effector functions — including complement deposition (ADCD) and neutrophil phagocytosis (ADNP) — likely driven by elevated milk viral loads. In contrast, non-transmitting mothers showed p24-specific antibody responses inversely correlated with lower viral loads, suggesting better viral control. Fc glycosylation analysis revealed higher digalactosylated IgG in transmitting mothers, linked to enhanced neutrophil inflammatory cytokine release. IgG depletion experiments confirmed that IgG, not IgA, was the primary driver of neutrophil activation in transmitting mothers. Overall, these findings highlight distinct humoral immune signatures associated with HIV transmission risk or protection during breastfeeding and provide mechanistic insights relevant for maternal vaccine development and Fc-engineered broadly neutralizing antibody prevention strategies. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M36HEJZR0A | ||||||||||||
| Subjects: | 100 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY3511: Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages | |||||||
| Status: | New | ||||||
| Description: | The authors initially developed animal models to investigate the mechanisms of cross-protection by contemporary FLUBV lineages. Then, they used EMPEM to visualize the polyclonal antibody response to the FLUBV lineages. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3A9YKDXDI | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3645: Adjuvants enhance seasonal influenza vaccines | |||||||||||||
| Status: | New | ||||||||||||
| Description: | Mice were vaccinated with either Fluzone mixed with PBS, Fluzone mixed with a squalane oil-in-water adjuvant (Addavax), or Fluzone mixed with a combinatory synthetic toll-like receptor (TLR) 4 and TLR7/8 agonist (TRAC478). Mice were then challenged with either H1N1 (BR/18) or H3N2 (SW/13). Results showed that the addition of an adjuvant-- especially TRAC478-- to the Fluzone seasonal influenza vaccine elicits a higher level of antibodies in mice and increased protection compared to unadjuvanted Fluzone. This distinction was more prominent following a single vaccination. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3FN48W7TO | ||||||||||||
| Subjects: | 0 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: | None | ||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY3648: Immunogenicity of the Foldon trimerization domain | ||||||||||||||||
| Status: | New | |||||||||||||||
| Description: | Repeated use of vaccine antigens that contain the Foldon domain may induce unintended antibody responses that interfere with immune protection and lower vaccine effectiveness. In this study, the feasibility of immunosilencing the Foldon domain was assessed through engineered glycosylation. Using structural analysis, three solvent-exposed sites to incorporate N-linked glycosylation motifs into the Foldon sequence were selected. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M3N5KLW5MX | |||||||||||||||
| Subjects: | 0 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: | None | |||||||||||||||
| Clinical Assessments: | None | |||||||||||||||
| Release Notes: |
|
|||||||||||||||
| SDY3650: Sequencing of SARS-CoV-2 and Influenza Monoclonal Antibodies | ||||||||||
| Status: | New | |||||||||
| Description: | Optimization of the antibody could potentially increase the effectiveness of vaccines. The data was assessed via de novo sequence. The CDR sequences were observed and validated through ELISA binding assays. The methodology results in an almost complete antibody sequence to increase the effectiveness of vaccines. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3R4BHISFY | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3658: Local B-cell immunity and durable memory following live-attenuated influenza intranasal vaccination of humans | ||||||||||
| Status: | New | |||||||||
| Description: | The authors examined human mucosal and systemic immunity after seasonal intramuscular or intranasal vaccination. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3BRH4SQSY | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3662: Single-cell profiling of circulating immune cells in healthy older adults | ||||||||||
| Status: | New | |||||||||
| Description: | To characterize immune signatures of aging, we recruited healthy, non-frail older adults (aged 64 and above) and profiled their peripheral blood mononuclear cells via 5’ single-cell RNA sequencing along with paired T-cell receptor (TCR) sequencing. CMV serostatus was quantified using IgG ELISA. Integrating these datasets, we identified multiple subsets of T cells associated with CMV seropositivity. In addition, we uncovered CMV-specific TCR clones in CMV-positive individuals. Specifically, CMV-positive older adults displayed reduced diversity of TCRs in GZMK+ CD8+ T cells, Th1, and CD4+/CD8+ TEMRA subsets. This data was also used to test the performance of CMVerify, a machine learning classifier, in predicting CMV serostatus. Overall, this study uncovers novel alterations in immune cells associated with latent CMV infection in older adults. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3A0WHEKES | |||||||||
| Subjects: | 20 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: | None | |||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3663: Genetically diverse influenza antibodies highlight the role of IG germline gene variation and inform population-comprehensive vaccine strategies | ||||||||||
| Status: | New | |||||||||
| Description: | The authors describe HA central stem-targeting broadly neutralizing antibodies that utilize IGHD3-3 recombined with diverse IGHV genes. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3ZM8RL7KK | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3664: Transient lung eosinophilia during breakthrough influenza infection in vaccinated mice is associated with protective and balanced Type 1/2 immune responses | |||||||
| Status: | New | ||||||
| Description: | The authors assess the eosinophil response in mice with breakthrough influenza infections | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M388CB0XUK | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3665: Protective immune responses against influenza following intranasal vaccination | ||||||||||
| Status: | New | |||||||||
| Description: | Mice were vaccinated intranasally with Fluzone or Flublok mixed with adjuvant, challenged with H1N1 BR/18 or H3N2 SW/13, and assessed for protective immune responses against H1N1, H3N2, and B influenza viruses by means of antibody and cellular assays conducted on collected sera and organs. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3893XQIA8 | |||||||||
| Subjects: | 0 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY3666: Influenza vaccine based on AS03-adjuvanted chimeric HA induces long-lived stalk-specific plasma cells in bone marrow and lymph nodes of nonhuman primates | |||||||||||||||||||
| Status: | New | ||||||||||||||||||
| Description: | The authors investigate the durability of humoral immunity induced by an influenza vaccine based on AS03-adjuvanted chimeric hemagglutinin in nonhuman primates | ||||||||||||||||||
| Program/Contract: |
|
||||||||||||||||||
| DOI: | 10.21430/M35RLB0VO4 | ||||||||||||||||||
| Subjects: | 0 | ||||||||||||||||||
| Study PI, contact: |
|
||||||||||||||||||
| Publications: |
|
||||||||||||||||||
| Resources: |
|
||||||||||||||||||
| Assays: | None | ||||||||||||||||||
| Clinical Assessments: | None | ||||||||||||||||||
| Release Notes: |
|
||||||||||||||||||
| SDY3670: Disease modulation by TIV vaccination during secondary pneumococcal infections in influenza-infected mice | |||||||
| Status: | New | ||||||
| Description: | The investigators present a preclinical mouse model to examine the impact of influenza vaccination in scenarios involving single infections with influenza A virus H1N1 (NC99) or Spn serotype 1, coinfection with NC99 and Spn, or NC99 infection followed by Spn infection seven days later. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3C2VVFXEU | ||||||
| Subjects: | 0 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: | None | ||||||
| Clinical Assessments: | None | ||||||
| Release Notes: |
|
||||||
| SDY3678: B cell imprinting in children impairs antibodies to the haemagglutinin stalk | ||||||||||||||||
| Status: | New | |||||||||||||||
| Description: | The authors characterize the B cell responses of young children after consecutive first infections with divergent H1N1 and H3N2 strains of influenza. | |||||||||||||||
| Program/Contract: |
|
|||||||||||||||
| DOI: | 10.21430/M38FVCDDT4 | |||||||||||||||
| Subjects: | 0 | |||||||||||||||
| Study PI, contact: |
|
|||||||||||||||
| Publications: |
|
|||||||||||||||
| Resources: |
|
|||||||||||||||
| Assays: | None | |||||||||||||||
| Clinical Assessments: | None | |||||||||||||||
| Release Notes: |
|
|||||||||||||||
Updated Studies
| SDY4: Risk Factors in Atopic Dermatitis for the Development of Eczema Herpeticum (ADRN-06) | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | DETAILED_DESCRIPTION AD is characterized by skin inflammation and recurrent skin infections. In addition, people with AD may have a severe and sometimes fatal reaction to the smallpox vaccine called EV. KLH is a carrier protein that can be used to deliver antibodies to the body. However KLH itself, may cause an immune response. The purpose of this study is to determine the body's reaction to pure KLH in people without AD. This will be used to establish a baseline immune response and may be compared to the immune response in people with AD during future studies. This study will last 8 weeks and will have 11 study visits. Participants in this study will be randomly assigned to 1 of 4 groups. All participants will receive their immunizations at Visits 5 and 6.
|
||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M398H5TAXP | ||||||||||||
| Subjects: | 235 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: |
|
||||||||||||
| Release Notes: |
|
||||||||||||
| SDY1092: Transcriptional responses induced by controlled human malaria infection (CHMI) | ||||||||||
| Status: | Updated | |||||||||
| Description: | Whole blood RNA-Seq was applied to investigate gene expression kinetics in Tanzanian males who underwent controlled malaria infection by intradermal injection with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Building on PfSPZ challenge study: ClinicalTrials.gov Identifier: NCT01540903, PUBMED:PMC4155546 | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M32AARFE8U | |||||||||
| Subjects: | 10 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY2367: Maternal immune response and placental antibody transfer by trimester of COVID-19 vaccination | ||||||||||
| Status: | Updated | |||||||||
| Description: | The availability of three COVID-19 vaccines in the United States provides an unprecedented opportunity to examine how vaccine platforms and timing of vaccination in pregnancy impact maternal and neonatal immunity. Here, we characterize the antibody profile after Ad26.COV2.S, mRNA-1273 or BNT162b2 vaccination in 158 pregnant individuals and evaluate transplacental antibody transfer by profiling maternal and umbilical cord blood in 175 maternal-neonatal dyads. These analyses reveal lower vaccine-induced functions and Fc receptor-binding after Ad26.COV2.S compared to mRNA vaccination and subtle advantages in titer and function with mRNA-1273 versus BN162b2. mRNA vaccines have higher titers and functions against SARS-CoV-2 variants of concern. First and third trimester vaccination results in enhanced maternal antibody-dependent NK-cell activation, cellular and neutrophil phagocytosis, and complement deposition relative to second trimester. Higher transplacental transfer ratios following first and second trimester vaccination may reflect placental compensation for waning maternal titers. These results provide novel insight into the impact of platform and trimester of vaccination on maternal humoral immune response and transplacental antibody transfer. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3GUZCJM05 | |||||||||
| Subjects: | 219 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY2552: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes | ||||||||||
| Status: | Updated | |||||||||
| Description: | The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. Proteomic deconvolution of the IgG repertoire to the spike glycoprotein in convalescent subjects revealed that the response is directed predominantly (greater than 80 percent) against epitopes residing outside the receptor binding domain (RBD). In one subject, just four IgG lineages accounted for 93.5 percent of the response, including an amino (N)-terminal domain (NTD)-directed antibody that was protective against lethal viral challenge. Genetic, structural, and functional characterization of a multidonor class of public antibodies revealed an NTD epitope that is recurrently mutated among emerging SARS-CoV-2 variants of concern. These data show that public NTD-directed and other non-RBD plasma antibodies are prevalent and have implications for SARS-CoV-2 protection and antibody escape. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/m3yhp9kyvl | |||||||||
| Subjects: | 4 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: |
|
|||||||||
| Release Notes: |
|
|||||||||
| SDY2597: Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Influenza virus alters glycosylation patterns on its surface exposed glycoproteins to evade host adaptive immune responses. The viral hemagglutinin (HA), in particular the H3 subtype, has increased its overall surface glycosylation since its introduction in 1968. We previously showed that modulating predicted N-linked glycosylation sites on H3 A/Hong Kong/1/1968 HA identified a conserved epitope at the HA interface. This epitope is occluded on the native HA trimer but is likely exposed during HA breathing on the virion surface. Antibodies directed to this site are protective via an ADCC-mediated mechanism. This glycan engineering strategy made an otherwise subdominant epitope dominant in the murine model. Here, we asked whether cysteine stabilization of the hyperglycosylated HA trimer could reverse this immunodominance by preventing access to the interface epitope and focus responses to the HA receptor binding site (RBS). While analysis of serum responses from immunized mice did not show a redirection to the RBS, cysteine stabilization did result in an overall reduction in immunogenicity of the interface epitope. Thus, glycan engineering and cysteine stabilization are two strategies that can be used together to alter immunodominance patterns to HA. These results add to rational immunogen design approaches used to manipulate immune responses for the development of next-generation influenza vaccines. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3JN37U7PR | ||||||||||||
| Subjects: | 39 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: |
|
||||||||||||
| Release Notes: |
|
||||||||||||
| SDY2617: Placental transfer of maternal COVID-19 vaccine-induced antibodies in infants | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | Completion of a COVID-19 vaccination series during pregnancy effectively reduces COVID-19 hospitalization among infants less than 6 months of age. The dynamics of transplacental transfer of maternal vaccine-induced antibodies and their persistence in infants at 2,6,9 and 12 months have implications for new vaccine development and optimal timing of vaccine administration in pregnancy. We evaluated anti-COVID antibody IgG subclass, Fc-receptor binding profile, and activity against wild-type Spike and RBD plus five variants of concern (VOCs) in 153 serum samples from 100 infants. Maternal IgG1 and IgG3 responses persisted in 2- and 6-month infants to a greater extent than the other IgG subclasses, with high persistence of antibodies binding placental neonatal Fc-receptor and FcγR3A. Lowest persistence was observed against the Omicron RBD-specific region. Maternal vaccine timing, placental Fc-receptor binding capabilities, antibody subclass, fetal sex, and VOC all impact the persistence of antibodies in infants through 12 months of age. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3B6120AR6 | ||||||||||||
| Subjects: | 195 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY2618: Accelerated Weight Gain Among Infants With In Utero COVID-19 exposure | ||||||||||
| Status: | Updated | |||||||||
| Description: | We conducted a longitudinal cohort study leveraging a prospectively enrolled perinatal biorepository among 149 infants with in-utero COVID-19 exposure and 127 unexposed controls. Weight, length, and body mass index (BMI) were abstracted from health records at 0, 2, 6, and 12 months and standardized using World Health Organization growth charts. Analyses were adjusted for maternal age, ethnicity, parity, insurance, and BMI, as well as infant sex, birthdate, and breastfeeding. After our data collection and analysis, we evidenced that infants with in utero COVID-19 exposure exhibited lower birth weight and accelerated weight gain in the first year of life, which may be harbingers of downstream cardiometabolic pathology. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M33IM6KHA3 | |||||||||
| Subjects: | 276 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: | None | |||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY2705: Characterization of the SARS-CoV-2 Mu variant | ||||||||||
| Status: | Updated | |||||||||
| Description: | In a live virus neutralization assay with serum samples from individuals vaccinated with the Pfizer/BioNTech or Moderna mRNA vaccines, we measured neutralization antibody titers against B.1.621, an early isolate (spike 614D), and a variant of concern (B.1.351, Beta variant). | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3AK8N7KTE | |||||||||
| Subjects: | 100 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||
| SDY2827: Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses | |||||||||
| Status: | Updated | ||||||||
| Description: | The authors characterize six human monoclonal antibodies isolated from two H3N2-infected donors that showed robust binding against the conserved internal nucleoprotein or matrix protein 1 influenza A virus strains. | ||||||||
| Program/Contract: |
|
||||||||
| DOI: | 10.21430/M33LLW8CHV | ||||||||
| Subjects: | 84 | ||||||||
| Study PI, contact: |
|
||||||||
| Publications: |
|
||||||||
| Resources: |
|
||||||||
| Assays: |
|
||||||||
| Clinical Assessments: |
|
||||||||
| Release Notes: |
|
||||||||
| SDY2917: Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth | |||||||||||||
| Status: | Updated | ||||||||||||
| Description: | A prospective cohort study was conducted at 2 academic medical centers between September 20, 2023 and March 21, 2024, enrolling 124 individuals who received the respiratory syncytial virus vaccine during pregnancy. Infant capillary blood was collected at 2 months of age from 29 of the infants. Maternal and cord immunoglobulin G levels achieved by respiratory syncytial virus vaccination were compared to those associated with maternal natural respiratory syncytial virus infection, using banked blood from 20 maternal:cord dyads collected prior to the availability of the maternal respiratory syncytial virus vaccine. Levels of immunoglobulin G against respiratory syncytial virus strain A2 and B fusion (F) and attachment (G) proteins and against pertussis toxin (as a comparator antigen from a vaccine routinely administered earlier in pregnancy) were measured using a Binding Antibody Multiplex Assay. Differences in titers between vaccination and natural infection were examined using Wilcoxon rank-sum test. Differences in cord:maternal transfer ratios and 2-month infant antibody levels by timing of maternal vaccination were evaluated by Kruskal-Wallis testing. | ||||||||||||
| Program/Contract: |
|
||||||||||||
| DOI: | 10.21430/M3E6U41NW0 | ||||||||||||
| Subjects: | 171 | ||||||||||||
| Study PI, contact: |
|
||||||||||||
| Publications: |
|
||||||||||||
| Resources: |
|
||||||||||||
| Assays: |
|
||||||||||||
| Clinical Assessments: | None | ||||||||||||
| Release Notes: |
|
||||||||||||
| SDY2963: A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes | |||||||
| Status: | Updated | ||||||
| Description: | Seasonal influenza vaccines offer little protection against pandemic influenza virus strains. It is difficult to create effective prepandemic vaccines because it is uncertain which influenza virus subtype will cause the next pandemic. In this work, we developed a nucleoside-modified messenger RNA (mRNA)-lipid nanoparticle vaccine encoding hemagglutinin antigens from all 20 known influenza A virus subtypes and influenza B virus lineages. This multivalent vaccine elicited high levels of cross-reactive and subtype-specific antibodies in mice and ferrets that reacted to all 20 encoded antigens. Vaccination protected mice and ferrets challenged with matched and mismatched viral strains, and this protection was at least partially dependent on antibodies. Our studies indicate that mRNA vaccines can provide protection against antigenically variable viruses by simultaneously inducing antibodies against multiple antigens. | ||||||
| Program/Contract: |
|
||||||
| DOI: | 10.21430/M3ZUEULG98 | ||||||
| Subjects: | 196 | ||||||
| Study PI, contact: |
|
||||||
| Publications: |
|
||||||
| Resources: |
|
||||||
| Assays: |
|
||||||
| Clinical Assessments: |
|
||||||
| Release Notes: |
|
||||||
| SDY3123: Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants | |||||||||||
| Status: | Updated | ||||||||||
| Description: | Here, the authors evaluated the local and systemic humoral and cellular immune responses to adjuvanted recombinant N1 NA. | ||||||||||
| Program/Contract: |
|
||||||||||
| DOI: | 10.21430/M3GKZBI89W | ||||||||||
| Subjects: | 142 | ||||||||||
| Study PI, contact: |
|
||||||||||
| Publications: |
|
||||||||||
| Resources: |
|
||||||||||
| Assays: |
|
||||||||||
| Clinical Assessments: |
|
||||||||||
| Release Notes: |
|
||||||||||
| SDY3422: Longitudinal analysis of influenza vaccination and DNA methylation regulation | ||||||||||
| Status: | Updated | |||||||||
| Description: | DNA methylation changes to components of the RIG-I pathway are associated with vaccine effectiveness. Computational analysis performed via HAI assay, paired t-test, and differently methylated sites assess how they contribute to the immune response. | |||||||||
| Program/Contract: |
|
|||||||||
| DOI: | 10.21430/M3X9OYUT1R | |||||||||
| Subjects: | 96 | |||||||||
| Study PI, contact: |
|
|||||||||
| Publications: |
|
|||||||||
| Resources: |
|
|||||||||
| Assays: |
|
|||||||||
| Clinical Assessments: | None | |||||||||
| Release Notes: |
|
|||||||||